Literature DB >> 11855917

Changes in the microvascular architecture of colorectal liver metastases following the administration of SMANCS/lipiodol.

Darshini Kuruppu1, C Christophi, Hiroshi Maeda, Paul E O'Brien.   

Abstract

BACKGROUND: Liver metastases are the major cause of death for patients with colorectal cancer. Surgical resection is at present the only curative option. Styrene maleic acid neocarzinostatin [SMANCS/Lipiodol (S/L)] targets the unique vascular architecture of tumor blood vessels, which are hyperpermeable and lack a well-developed lymphatic system. Here we report changes in the microvascular architecture of liver metastases by scanning electron microscopy (SEM) following the administration of S/L.
MATERIALS AND METHODS: Liver metastases were induced by the intrasplenic injection of dimethylhydrazine induced colon cancer cells in mice. In this model tumor angiogenesis occurs at day 10, while exponential tumor growth occurs at day 16. Changes in the tumor microvasculature were observed at 3 weeks following treatment with S/L at these time points by SEM of corrosion casts.
RESULTS: Tumors treated with S/L at day 10 appear similar to day 10 controls. Tumor vessels, 50 +/- 18 microm in diameter, are easily identified from hepatic vessels. Within the hepatic sinusoids are avascular spaces, 144 +/- 60 microm in diameter, which correspond to tumor cell aggregates at the initial stages of growth. Similarly, day 16 treated tumors appear comparable to day 16 controls. These vessels are narrower (84 +/- 32 microm vs. 150 +/- 70 microm) than their control counterparts. This is in contrast to vessels (216 +/- 36 microm in diameter) of a complex nature at 3 weeks.
CONCLUSIONS: S/L exerts a marked and immediate effect on the tumor microvessels at both the angiogenic and the exponential phases of tumor growth. This agent is effective at the microvascular level during inhibition of metastatic growth.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11855917     DOI: 10.1006/jsre.2001.6299

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  2 in total

1.  Passive targeting of nanoparticles to cancer: A comprehensive review of the literature.

Authors:  Remon Bazak; Mohamad Houri; Samar El Achy; Wael Hussein; Tamer Refaat
Journal:  Mol Clin Oncol       Date:  2014-07-23

2.  Etk/Bmx regulates proteinase-activated-receptor1 (PAR1) in breast cancer invasion: signaling partners, hierarchy and physiological significance.

Authors:  Irit Cohen; Myriam Maoz; Hagit Turm; Sorina Grisaru-Granovsky; Bella Maly; Beatrice Uziely; Einat Weiss; Rinat Abramovitch; Eithan Gross; Oded Barzilay; Yun Qiu; Rachel Bar-Shavit
Journal:  PLoS One       Date:  2010-06-15       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.